Johnson & Johnson (JNJ) achieved a Q1 revenue of $24.06 billion, marking a 9.9% year-over-year increase and surpassing analyst consensus with an adjusted EPS of $2.70. While the company grapples with talc-related lawsuits, it remains a strong dividend stock with a 64-year history of dividend increases and currently boasts a yield of 2.3%. Analysts project a 7% growth in sales for 2026, supported by robust new product pipelines and a confident market outlook, evidenced by a 59.53% rise in share prices over the past year.
“Johnson & Johnson · number of stock splits · 6 · true”
“Johnson & Johnson · founded · 1886”
“Johnson & Johnson (JNJ) · is a great dividend stock right now · true”
“J&J · is · top pick · true”
“Johnson & Johnson (JNJ) · is considered · great dividend stock · true”
“Johnson & Johnson · shares have lost · about 3.5% · since last earnings report”
“Johnson & Johnson · is in the DJIA · true · true”
“Johnson & Johnson · announced · a series of medical advances · including the global launch of its Shockwave C2 Aero coronary IVL catheter, positive Phase 2b and Phase 3 data in inflammatory bowel disease, and first-in-human results for its OTTAVA robotic surgical system”
“Johnson & Johnson · is one of the world's largest · pharmaceutical and medical device companies · true”
“Johnson & Johnson · has raised its dividend · annually for 64 consecutive years · true”
“Johnson & Johnson · currently pays a forward dividend yield of · 2.3% · true”
“Johnson & Johnson · has a · strong research and development (R&D) pipeline · true”
